#1 Clinical Trials Search in Europe

Peginterferon Beta-1A

Peginterferon Beta-1A, also known as Plegridy, is a medication being studied in clinical trials for the treatment of multiple sclerosis (MS). This article summarizes key findings from several clinical trials evaluating the safety, efficacy, and patient experiences with Peginterferon Beta-1A in people with relapsing forms of MS. The trials examine various aspects including dosing, side effects, quality of life impacts, and comparisons to other MS treatments.

Table of Contents

What is Peginterferon Beta-1a?

Peginterferon Beta-1a is a medication used to treat multiple sclerosis (MS). It’s known by several names, including:

  • Plegridy
  • BIIB017
  • PEG IFN β-1a
  • PEGylated Interferon Beta-1a
This medication is a modified version of interferon beta-1a, a protein that occurs naturally in our bodies. The “PEG” in its name stands for polyethylene glycol, a substance attached to the interferon molecule to make it last longer in the body.[1][2]

How Does Peginterferon Beta-1a Work?

Peginterferon Beta-1a works by mimicking the body’s natural interferon, which helps regulate the immune system. In multiple sclerosis, the immune system mistakenly attacks the protective covering of nerve fibers (called myelin) in the brain and spinal cord. By modulating the immune system, Peginterferon Beta-1a helps reduce this attack, potentially slowing down the progression of MS and reducing symptoms.[1]

What Conditions Does Peginterferon Beta-1a Treat?

Peginterferon Beta-1a is primarily used to treat relapsing forms of multiple sclerosis (MS), including:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups (relapses) followed by periods of recovery (remissions).
  • Active Secondary Progressive Multiple Sclerosis (SPMS): A form of MS that develops in some people with RRMS, where disability progressively worsens with or without relapses.
The medication is designed to reduce the frequency of relapses and slow the accumulation of physical disability in people with these forms of MS.[2][3]

How is Peginterferon Beta-1a Administered?

Peginterferon Beta-1a is typically administered as a subcutaneous injection (an injection under the skin) every two weeks. The standard dose is 125 micrograms (μg). It’s usually provided in pre-filled syringes or auto-injector pens, allowing patients to self-administer the medication at home after proper training.[1][4]

Efficacy of Peginterferon Beta-1a

Clinical trials have shown that Peginterferon Beta-1a is effective in treating relapsing forms of MS. Key findings include:

  • Reduced Relapse Rate: The medication has been shown to significantly reduce the annualized relapse rate (ARR) in patients with relapsing MS. This means patients experienced fewer MS attacks over a year compared to those not taking the medication.[5]
  • Slowed Disability Progression: Studies have indicated that Peginterferon Beta-1a can slow the progression of physical disability in MS patients.[5]
  • Reduced Brain Lesions: MRI scans have shown that patients taking Peginterferon Beta-1a developed fewer new or enlarging brain lesions (areas of damage in the brain) compared to those not on the medication.[5]
These effects have been observed to last for extended periods, with some studies following patients for up to 4 years.[1]

Side Effects and Safety

Like all medications, Peginterferon Beta-1a can cause side effects. Common side effects include:

  • Flu-like symptoms: This includes chills, fever, muscle aches, and fatigue. These symptoms often improve over time and can be managed with over-the-counter pain relievers.
  • Injection site reactions: Redness, pain, or swelling at the injection site is common but usually mild.
  • Liver function changes: Regular blood tests may be needed to monitor liver function.
Less common but more serious side effects can include depression, seizures, and allergic reactions. It’s important to discuss all potential side effects with your healthcare provider.[2][3]

Patient Satisfaction and Quality of Life

Studies have also looked at how Peginterferon Beta-1a affects patients’ quality of life and satisfaction with treatment. Findings include:

  • Improved Treatment Satisfaction: Many patients reported higher satisfaction with Peginterferon Beta-1a compared to other injectable MS treatments, particularly due to the less frequent dosing schedule (every 2 weeks instead of multiple times per week).[6]
  • Quality of Life: Some patients reported improvements in various aspects of their quality of life, including physical functioning and fatigue levels.[4]
  • Work Productivity: There’s some evidence that treatment with Peginterferon Beta-1a may help improve work productivity in people with MS.[3]
However, it’s important to note that experiences can vary greatly between individuals.

Use in Special Populations

Research has also been conducted on the use of Peginterferon Beta-1a in specific groups:

  • Pregnancy: A pregnancy registry has been established to gather information on the effects of Peginterferon Beta-1a exposure during pregnancy. If you’re pregnant or planning to become pregnant, it’s crucial to discuss this with your healthcare provider.[7]
  • Pediatric Patients: Studies are ongoing to evaluate the safety and efficacy of Peginterferon Beta-1a in children and adolescents with MS aged 10 to 17 years.[8]
  • Patients with Kidney Problems: Research has been conducted to understand how kidney function affects the way the body processes Peginterferon Beta-1a.[9]

Ongoing Research

Research on Peginterferon Beta-1a is ongoing, with studies looking at various aspects such as:

  • Long-term safety and efficacy
  • Comparison with other MS treatments
  • Use in different patient populations
  • Impact on specific MS symptoms and quality of life measures
These studies aim to provide more information to help patients and healthcare providers make informed decisions about MS treatment.[2][8]

Aspect Details
Efficacy – Reduced annualized relapse rate by 36% vs placebo over 1 year – Decreased new/enlarging T2 lesions on MRI – Slowed disability progression in some patients
Safety – Most common side effects: injection site reactions, flu-like symptoms – Generally well-tolerated with mostly mild to moderate adverse events – No new safety concerns identified in long-term studies
Dosing – 125 μg subcutaneous injection every 2 weeks – Less frequent dosing compared to other interferon therapies
Patient Satisfaction – High satisfaction reported, especially regarding dosing convenience – Improvements in quality of life measures for many patients – Some patients reported less injection site pain compared to prior treatments
Comparisons – Similar efficacy to other interferon therapies – Potential advantages in convenience and adherence due to less frequent dosing – Transition studies showed maintained or improved outcomes when switching from other interferons

FAQ

  • What is Peginterferon Beta-1A? Peginterferon Beta-1A (brand name Plegridy) is a long-acting form of interferon beta-1a used to treat relapsing forms of multiple sclerosis. It is administered by subcutaneous injection every 2 weeks.
  • How effective is Peginterferon Beta-1A in treating MS? Clinical trials have shown Peginterferon Beta-1A to be effective in reducing relapse rates, slowing disability progression, and reducing brain lesions in people with relapsing MS compared to placebo. One study found it reduced the annualized relapse rate by 36% compared to placebo over 1 year.
  • What are the most common side effects of Peginterferon Beta-1A? The most commonly reported side effects in clinical trials were injection site reactions, flu-like symptoms (such as fever, chills, muscle aches), and headache. Most side effects were mild to moderate in severity.
  • How does Peginterferon Beta-1A compare to other MS treatments? Some trials have compared Peginterferon Beta-1A to other interferon therapies. While direct comparisons are limited, Peginterferon Beta-1A appears to have similar efficacy with the advantage of less frequent dosing (every 2 weeks vs. multiple times per week for other interferons).
  • How do patients rate their satisfaction with Peginterferon Beta-1A? Patient-reported outcomes in clinical trials indicate generally high satisfaction with Peginterferon Beta-1A, particularly regarding the convenience of less frequent injections. Many patients reported improvements in quality of life measures compared to prior treatments.

Ongoing Clinical Trials on Peginterferon Beta-1A

  • Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Peginterferon Beta-1a for Children and Teens with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Hungary Slovakia

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Annualized Relapse Rate (ARR): The average number of relapses a person with MS experiences per year. This is a key measure of disease activity and treatment efficacy in MS clinical trials.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis. The EDSS scale ranges from 0 to 10, with higher scores indicating greater disability.
  • Gadolinium-enhancing (Gd+) lesions: Active inflammatory lesions in the brain or spinal cord that can be seen on MRI scans when contrast dye is used. These indicate current disease activity in MS.
  • Injection site reactions (ISRs): Local skin reactions such as redness, pain, or swelling at the site where a medication is injected. This is a common side effect with injectable MS therapies.
  • Relapsing-Remitting Multiple Sclerosis (RRMS): The most common form of MS, characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.
  • T2 hyperintense lesions: Areas of damage in the brain or spinal cord caused by MS that appear bright on certain types of MRI scans. The number and size of these lesions are often used to track disease progression.
  • Treatment Satisfaction Questionnaire for Medication (TSQM): A validated survey tool used to assess patients' satisfaction with their medication in terms of effectiveness, side effects, convenience, and overall satisfaction.

References

  1. https://clinicaltrials.gov/study/NCT01332019
  2. https://clinicaltrials.gov/study/NCT02230969
  3. https://clinicaltrials.gov/study/NCT03177083
  4. https://clinicaltrials.gov/study/NCT02234869
  5. https://clinicaltrials.gov/study/NCT00906399
  6. https://clinicaltrials.gov/study/NCT02587065
  7. https://clinicaltrials.gov/study/NCT01911767
  8. https://clinicaltrials.gov/study/NCT03870763
  9. https://clinicaltrials.gov/study/NCT01119781